Indivior Pharmaceuticals Inc
NASDAQ:INDV · NASDAQ Global Select
+$0.26 today
Vol 2.82M · Avg 2.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:INDV · Revenue to Net Income
Key Ratios
Analysis
$1.3B of revenue converted into $251.0M of net income for the selected period. Gross margin is 83.1% and net margin is 19.0%, showing how much revenue survives after costs and taxes. EPS is $1.98, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B +4.3% | $1.2B +8.7% | $1.1B +21.3% | $901.0M +13.9% | $791.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $246.0M +6.5% | $231.0M +32.8% | $174.0M +15.2% | $151.0M +18.9% | $127.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $993.0M +3.8% | $957.0M +4.1% | $919.0M +22.5% | $750.0M +13.0% | $664.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 80.1% -0.4pp | 80.6% -3.5pp | 84.1% +0.8pp | 83.2% -0.7pp | 83.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $97.0M -9.3% | $107.0M -7.8% | $116.0M +56.8% | $74.0M +42.3% | $52.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $634.0M +2.6% | $618.0M +8.6% | $569.0M +21.3% | $469.0M +8.8% | $431.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $728.0M -21.3% | $925.0M -14.0% | $1.1B +29.4% | $831.0M +84.3% | $451.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $20.0M -31.0% | $29.0M +93.3% | $15.0M -6.3% | $16.0M -27.3% | $22.0M | $374.2M | $1.2B | $631.8M |
| EBITDA | $304.0M +261.9% | $84.0M +184.8% | -$99.0M -115.2% | -$46.0M -119.3% | $238.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 24.5% +17.5pp | 7.1% +16.1pp | -9.1% -4.0pp | -5.1% -35.2pp | 30.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $265.0M +728.1% | $32.0M +120.5% | -$156.0M -92.6% | -$81.0M -138.0% | $213.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 21.4% +18.7pp | 2.7% +17.0pp | -14.3% -5.3pp | -9.0% -35.9pp | 26.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $22.0M -4.3% | $23.0M -46.5% | $43.0M +126.3% | $19.0M +375.0% | $4.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $45.0M +9.8% | $41.0M +17.1% | $35.0M +20.7% | $29.0M +11.5% | $26.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$26.0M -44.4% | -$18.0M -357.1% | $7.0M +187.5% | -$8.0M +65.2% | -$23.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $239.0M +1607.1% | $14.0M +109.4% | -$149.0M -67.4% | -$89.0M -146.8% | $190.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 19.3% +18.1pp | 1.2% +14.8pp | -13.6% -3.8pp | -9.9% -33.9pp | 24.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $29.0M +163.6% | $11.0M +155.0% | -$20.0M +54.5% | -$44.0M -193.3% | -$15.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $210.0M +10400.0% | $2.0M +101.6% | -$129.0M -193.2% | -$44.0M -121.5% | $205.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | 16.9% +16.8pp | 0.2% +12.0pp | -11.8% -6.9pp | -4.9% -30.8pp | 25.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +11025.8% | $0 +3.4% | $0 +103.9% | -$0 -126.8% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +10833.3% | $0 +6.4% | $0 +103.8% | -$0 -128.2% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $125.0M -5.3% | $132.0M -3.9% | $137.3M -1.2% | $139.0M -4.6% | $145.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $128.0M -3.8% | $133.0M -6.2% | $141.8M +2.0% | $139.0M -9.9% | $154.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Lantheus Holdings, Inc.
NASDAQ:LNTH
$6.75B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.94B
Hinge Health, Inc.
NYSE:HNGE
$5.16B
Amneal Pharmaceuticals, Inc.
NASDAQ:AMRX
$5.13B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.76B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.67B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.58B
Option Care Health, Inc.
NASDAQ:OPCH
$3.47B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.56B
ADMA Biologics, Inc.
NASDAQ:ADMA
$1.94B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does INDV generate?
Indivior Pharmaceuticals Inc (INDV) reported $1.24B of revenue in fiscal 2025.
Is INDV profitable?
Indivior Pharmaceuticals Inc (INDV) reported $210.00M of net income, with a net margin of 16.9%.
Explore More
Continue the stock analysis
Jump to another research area for this company.